EGFR and lung cancer: Similarly, some studies have shown that activation of STAT3/Bcl-2/caspase 3 signaling can promote apoptosis of NSCLC cells [17, 43], and acquired resistance of EGFR-mutated lung cancer to TKI treatment is related to the anti-apoptosis effect of the PARP pathway [44].